SCHEMBL5034484

SCHEMBL5034484

O=C(NCc1cccc(CC2(C(=O)O)CCCO2)c1)c1ccc(Cl)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
HPGD P15428 3/20 0.42
TMEM97 Q5BJF2 2/20 0.42
SIGMAR1 Q99720 2/20 0.42
GAA P10253 1/20 0.42
PTGER4 P35408 1/20 0.42
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
APEX1 P27695 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
P2RX7 Q99572 1/20 0.40
POLB P06746 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031993 0.91 HPGD (0.42) LMNAHTTHPGDGAACYP1A2
SCHEMBL5034512 0.90 CHRM3 (0.42) PTGER4PPARGPPARA
SCHEMBL5034450 0.86 ALDH1A1 (0.39) HPGDGAAPTGER4ALDH1A1SMN1; SMN2
SCHEMBL5032927 0.86 ALDH1A1 (0.43) LMNAHPGDALDH1A1SMN1; SMN2CYP3A4
SCHEMBL5029916 0.86 HRH3 (0.39) ALDH1A1SMN1; SMN2NPC1RAB9AAPEX1
SCHEMBL5029835 0.85 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CYP3A4NPC1RAB9A
SCHEMBL5034531 0.83 PPARA (0.41) LMNAHPGDPPARGPPARARECQL
SCHEMBL5029862 0.82 EPHX2 (0.40) HTTGAASMN1; SMN2CYP1A2CYP3A4
SCHEMBL5034509 0.81 HDAC1 (0.41) LMNAHPGDNPC1PPARGPPARA
SCHEMBL5034446 0.80 SCD (0.41) LMNAPTGER4PPARGPPARATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371777-B2 Cyclic compound and PPAR agonist EISAI CO., LTD. (JP) 2008-05-13 US disclosed
US-7371777-B2 Cyclic compound and PPAR agonist EISAI CO., LTD. (JP) 2008-05-13 US disclosed
US-7371777-B2 Cyclic compound and PPAR agonist EISAI CO., LTD. (JP) 2008-05-13 US disclosed
US-20050014833-A1 Cyclic compound and ppar agonist EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452521-A1 CYCLIC COMPOUND AND PPAR AGONIST Eisai Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014833-A1 Cyclic compound and ppar agonist PPARA, PPARG, PPARD LMNA 1951/4885HTT 4174/4885HPGD 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.